On January 23, 2019, BioSpecifics Technologies Corp. announced that Dr. Ronald Law, the Company’s Senior Vice President of Business Development, would be assisting Mr. Thomas L. Wegman, the company’s President, with day-to-day operations of the company and the company’s Board of Directors has designated Dr. Law as an executive officer of the company, as of the Effective Date. Dr. Law has served in his current role with the company since November 2018, prior to which he served as a consultant to the company since July 2018. Previously, Dr. Law was the Chief Strategy Officer of Oramed Pharmaceuticals Inc., where he was responsible for the development of execution of scientific and business collaborations and partnerships, as well as the identification of new targets and indications for its platform oral peptide delivery technology and pipeline expansion Prior to that, he was a scientific consultant in oncology at Third Coast Therapeutics, a diabetes consultant at Doctor Evidence, and a business development consultant at PharmaIN Corporation. He also held several leadership and strategic roles at Takeda Pharmaceuticals International, spanning U.S. Medical Affairs, Global Medical Affairs, Corporate Strategic Planning, Global Scientific Affairs and Intelligence, and R&D External Innovation, most recently serving as Vice President, of New Frontier Science.